— Titan Pharmaceuticals (NASDAQ: TTNP) reported Q3 2019 loss of $0.18 per share, vs. $0.21 expected.
— Revenues fell 47% to approx. $0.9 million, vs. $0.7 million expected.
— Product revenues totaled approx. $0.2 million.
— Grant revenues totaled approx. $0.8 million.
— R&D expenses amounted to approx. $1.6 million.
— TTNP shares gained 1% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Seagate Technology beats Q1 earnings estimate: Infographic
Seagate Technology (NYSE: ALK) reported first-quarter 2022 financial results before the regular market hours on Friday. The company reported Q1 revenue of $3.12 billion, up 35% year-over-year and higher than
Infographic: Schlumberger (SLB) Q3 2021 Earnings Results
Schlumberger Limited (NYSE: SLB) came up with its third-quarter 2021 results on Friday. Revenue increased to $5.8 billion from $5.2 billion last year. Analysts had expected revenue of $5.09 billion.
Honeywell (HON) Q3 2021 Earnings: Key financials and quarterly highlights
Honeywell International Inc. (NASDAQ: HON) reported third quarter 2021 earnings results today. Sales increased 9% year-over-year to $8.4 billion but missed projections of $8.6 billion. On an organic basis, sales
